Ito et al., 2000 - Google Patents
Identification of SART3‐derived peptides capable of inducing HLA‐A2‐restricted and tumor‐specific CTLs in cancer patients with different HLA‐A2 subtypesIto et al., 2000
- Document ID
- 5768626246485362709
- Author
- Ito M
- Shichijo S
- Miyagi Y
- Kobayashi T
- Tsuda N
- Yamada A
- Saito N
- Itoh K
- Publication year
- Publication venue
- International journal of cancer
External Links
Snippet
We recently identified the SART3 antigen encoding shared tumor epitopes recognized by HLA‐A2402‐restricted and tumor‐specific CTLs. Our study investigated whether the SART3 antigen encodes peptides recognized by the HLA‐A2‐restricted CTLs. The HLA‐A2 …
- 102100016729 SART3 0 title abstract description 98
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ito et al. | Identification of SART3‐derived peptides capable of inducing HLA‐A2‐restricted and tumor‐specific CTLs in cancer patients with different HLA‐A2 subtypes | |
| Kikuchi et al. | Identification of a SART‐1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes | |
| Nukaya et al. | Identification of HLA‐A24 epitope peptides of carcinoembryonic antigen which induce tumor‐reactive cytotoxic T lymphocyte | |
| Jäger et al. | Clonal expansion of Melan A‐specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma‐associated peptides | |
| Ito et al. | Molecular basis of T cell-mediated recognition of pancreatic cancer cells | |
| Fujie et al. | A MAGE‐1‐encoded HLA‐A24‐binding synthetic peptide induces specific anti‐tumor cytotoxic T lymphocytes | |
| Nakao et al. | Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL | |
| Tanaka et al. | Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24 | |
| Nakatsura et al. | Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin‐like protein, originally defined by the SEREX method | |
| Eichmüller et al. | Serological detection of cutaneous T-cell lymphoma-associated antigens | |
| Slingluff Jr et al. | Direct analysis of tumor-associated peptide antigens | |
| Aarnoudse et al. | Interleukin‐2‐induced, melanoma‐specific T cells recognize CAMEL, an unexpected translation product of LAGE‐1 | |
| Harashima et al. | Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases | |
| Tanzarella et al. | Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family | |
| Imaizumi et al. | Expression of the tumor‐rejection antigen SART1 in brain tumors | |
| Ma et al. | Two new tumor‐specific antigenic peptides encoded by gene MAGE‐C2 and presented to cytolytic T lymphocytes by HLA‐A2 | |
| Kawano et al. | Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer | |
| Faure et al. | Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA‐A* 0201‐restricted epitopes | |
| Murayama et al. | Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides | |
| Nishizaka et al. | A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma | |
| Yamada et al. | Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes | |
| Tanaka et al. | Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery | |
| Tahara et al. | Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes | |
| Imai et al. | Identification of Lck‐derived peptides capable of inducing HLA‐A2‐restricted and tumor‐specific CTLs in cancer patients with distant metastases | |
| Monji et al. | Head and neck cancer antigens recognized by the humoral immune system |